keyword
MENU ▼
Read by QxMD icon Read
search

Bispecific antibody

keyword
https://www.readbyqxmd.com/read/28231426/engineering-of-anti-cd133-tri-specific-molecule-capable-of-inducing-nk-expansion-and-driving-antibody-dependent-cell-mediated-cytotoxicity-adcc
#1
Jörg U Schmohl, Martin Felices, Felix Oh, Alexander J Lenvik, Aaron M Lebeau, Jayanth Panyam, Jeffrey S Miller, Daniel A Vallera
Purpose: The selective elimination of cancer stem cells (CSCs) in tumor patients is a crucial goal because CSCs cause drug refractory relapse. To improve the current conventional bispecific immune-engager platform, a 16133 BiKE, consisting of scFvs binding FcγRIII (CD16) on NK cells and CD133 on carcinoma cells, was first synthesized and a modified IL-15 crosslinker capable of stimulating NK effector cells was introduced. Materials and Methods: DNA shuffling and ligation techniques were used to assemble and synthesize the 1615133 trispecific NK cell engager (TriKE)...
February 20, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28230658/engineering-antibody-like-inhibitors-to-prevent-and-treat-hiv-1-infection
#2
Matthew R Gardner, Michael Farzan
PURPOSE OF REVIEW: Here we discuss recently developed HIV-1 entry inhibitors that can target multiple epitopes on the HIV-1 envelope glycoprotein (Env), with an emphasis on eCD4-Ig. Some of these inhibitors are more potent and broader than any single antibody characterized to date. We also discuss the use of recombinant adeno-associated virus (rAAV) vectors as a platform for long-term expression of these inhibitors. RECENT FINDINGS: Much of the exterior of HIV-1 Env can be targeted by broadly neutralizing antibodies (bNAbs)...
February 21, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28228105/mesenchymal-stromal-cells-as-vehicles-of-tetravalent-bispecific-tandab-cd3-cd19-for-the-treatment-of-b-cell-lymphoma-combined-with-ido-pathway-inhibitor-d-1-methyl-tryptophan
#3
Xiaolong Zhang, Yuanyuan Yang, Leisheng Zhang, Yang Lu, Qing Zhang, Dongmei Fan, Yizhi Zhang, Yanjun Zhang, Zhou Ye, Dongsheng Xiong
BACKGROUND: Although blinatumomab, a bispecific T cell engaging antibody, exhibits high clinical response rates in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (B-ALL) and B cell non-Hodgkin's lymphoma (B-NHL), it still has some limitations because of its short half-life. Mesenchymal stromal cells (MSCs) represent an attractive approach for delivery of therapeutic agents to cancer sites owing to their tropism towards tumors, but their immunosuppression capabilities, especially induced by indoleamine 2,3-dioxygenase (IDO), should also be taken into consideration...
February 23, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28213794/selected-cytokine-pathways-in-rheumatoid-arthritis
#4
REVIEW
Mélissa Noack, Pierre Miossec
Rheumatoid arthritis (RA) is a chronic inflammatory disease leading to joint destruction. Cytokines play a key role in its pathogenesis. They contribute to the induction and maintenance of inflammation and thus provide therapeutic targets. Many cytokines are involved in RA, and this review focuses on a few critical ones: tumor necrosis factor (TNF), interleukin (IL)-6, IL-1, IL-17, and GM-CSF. TNF and IL-6 are both well-established targets in RA treatment, and new biologic agents are reaching the market. IL-1 represents a more complex cytokine as results in humans do not reach those in animal models...
February 17, 2017: Seminars in Immunopathology
https://www.readbyqxmd.com/read/28205621/cryogel-supported-stem-cell-factory-for-customized-sustained-release-of-bispecific-antibodies-for-cancer-immunotherapy
#5
Roberta Aliperta, Petra B Welzel, Ralf Bergmann, Uwe Freudenberg, Nicole Berndt, Anja Feldmann, Claudia Arndt, Stefanie Koristka, Marcello Stanzione, Marc Cartellieri, Armin Ehninger, Gerhard Ehninger, Carsten Werner, Jens Pietzsch, Jörg Steinbach, Martin Bornhäuser, Michael P Bachmann
Combining stem cells with biomaterial scaffolds provides a promising strategy for the development of drug delivery systems. Here we propose an innovative immunotherapeutic organoid by housing human mesenchymal stromal cells (MSCs), gene-modified for the secretion of an anti-CD33-anti-CD3 bispecific antibody (bsAb), in a small biocompatible star-shaped poly(ethylene glycol)-heparin cryogel scaffold as a transplantable and low invasive therapeutic machinery for the treatment of acute myeloid leukemia (AML). The macroporous biohybrid cryogel platform displays effectiveness in supporting proliferation and survival of bsAb-releasing-MSCs overtime in vitro and in vivo, avoiding cell loss and ensuring a constant release of sustained and detectable levels of bsAb capable of triggering T-cell-mediated anti-tumor responses and a rapid regression of CD33(+) AML blasts...
February 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28193052/characterization-of-chain-pairing-variants-of-bispecific-igg-expressed-in-a-single-host-cell-by-high-resolution-native-and-denaturing-mass-spectrometry
#6
Luis Schachner, Guanghui Han, Michael Dillon, Jianhui Zhou, Luke McCarty, Diego Ellerman, Yiyuan Yin, Christoph Spiess, Jennie R Lill, Paul J Carter, Wendy Sandoval
Bispecific antibodies, including bispecific IgG, show some promise in clinical trials as a means to extend the therapeutic potential of antibodies. Bispecific IgG can be made by separate expression and purification of each parent half antibody followed by in vitro reconstitution. Generating bispecific IgG by coexpression of two different light and heavy chains in a single host cell is potentially more efficient because it obviates the need for two separate cell lines and purification processes. However, this workflow may produce unwanted mispaired IgG species in addition to the desired bispecific IgG...
December 20, 2016: Analytical Chemistry
https://www.readbyqxmd.com/read/28188692/bioreactor-scale-up-and-protein-product-quality-characterization-of-piggybac-transposon-derived-cho-pools
#7
Yashas Rajendra, Sowmya Balasubramanian, Robert B Peery, James R Swartling, Neil A McCracken, Dawn L Norris, Christopher C Frye, Gavin C Barnard
Chinese hamster ovary (CHO) cells remain the most popular host for the production of biopharmaceutical drugs, particularly monoclonal antibodies (mAbs), bispecific antibodies and Fc-fusion proteins. Creating and characterizing the stable CHO clonally-derived cell lines (CDCLs) needed to manufacture these therapeutic proteins is a lengthy and laborious process. Therefore, CHO pools have increasingly been used to rapidly produce protein to support and enable preclinical drug development. We recently described the generation of CHO pools yielding mAb titers as high as 7...
February 11, 2017: Biotechnology Progress
https://www.readbyqxmd.com/read/28184223/fc-engineering-for-developing-therapeutic-bispecific-antibodies-and-novel-scaffolds
#8
REVIEW
Hongyan Liu, Abhishek Saxena, Sachdev S Sidhu, Donghui Wu
Therapeutic monoclonal antibodies have become molecules of choice to treat autoimmune disorders, inflammatory diseases, and cancer. Moreover, bispecific/multispecific antibodies that target more than one antigen or epitope on a target cell or recruit effector cells (T cell, natural killer cell, or macrophage cell) toward target cells have shown great potential to maximize the benefits of antibody therapy. In the past decade, many novel concepts to generate bispecific and multispecific antibodies have evolved successfully into a range of formats from full bispecific immunoglobulin gammas to antibody fragments...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28182247/translation-and-clinical-development-of-bispecific-t-cell-engaging-antibodies-for-cancer-treatment
#9
Theresa Yuraszeck, Sree Kasichayanula, Jonathan E Benjamin
Bispecific T Cell Engagers (BiTE®) antibody constructs enable a polyclonal T cell response to cell-surface tumor-associated antigens, bypassing the narrow specificities of T cell receptors and the need for antigen presentation through the Major Histocompatibility Complex pathways. Blinatumomab, a CD19xCD3 BiTE® antibody construct, received accelerated approval for the treatment of relapsed/refractory Philadelphia chromosome negative acute lymphoblastic leukemia. Herein we review the pharmacology, safety, and efficacy observed in studies of blinatumomab and other BiTE® antibody constructs...
February 9, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28157217/acute-myeloid-leukemia-targets-for-bispecific-antibodies
#10
REVIEW
S S Hoseini, N K Cheung
Despite substantial gains in our understanding of the genomics of acute myelogenous leukemia (AML), patient survival remains unsatisfactory especially among the older age group. T cell-based therapy of lymphoblastic leukemia is rapidly advancing; however, its application in AML is still lagging behind. Bispecific antibodies can redirect polyclonal effector cells to engage chosen targets on leukemia blasts. When the effector cells are natural-killer cells, both antibody-dependent and antibody-independent mechanisms could be exploited...
February 3, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/28153099/selective-blockade-of-the-ubiquitous-checkpoint-receptor-cd47-is-enabled-by-dual-targeting-bispecific-antibodies
#11
Elie Dheilly, Valéry Moine, Lucile Broyer, Susana Salgado-Pires, Zoë Johnson, Anne Papaioannou, Laura Cons, Sébastien Calloud, Stefano Majocchi, Robert Nelson, François Rousseau, Walter Ferlin, Marie Kosco-Vilbois, Nicolas Fischer, Krzysztof Masternak
CD47 is a ubiquitously expressed immune checkpoint receptor that is often upregulated in cancer. CD47 interacts with its counter-receptor SIRPα on macrophages and other myeloid cells to inhibit cancer cell phagocytosis and drive immune evasion. To overcome tolerability and "antigen sink" issues arising from widespread CD47 expression, we generated dual-targeting bispecific antibodies that selectively block the CD47-SIRPα interaction on malignant cells expressing a specific tumor-associated antigen; e.g., CD19 or mesothelin...
February 1, 2017: Molecular Therapy: the Journal of the American Society of Gene Therapy
https://www.readbyqxmd.com/read/28151644/improved-lysosomal-trafficking-can-modulate-the-potency-of-antibody-drug-conjugates
#12
Rachel M DeVay, Kathy Delaria, Guoyun Zhu, Charles Holz, Davide Foletti, Janette Sutton, Gary Bolton, Russell Dushin, Christine Bee, Jaume Pons, Arvind Rajpal, Hong Liang, David Shelton, Shu-Hui Liu, Pavel Strop
Antibody drug conjugates (ADCs) provide an efficacious and relatively safe means by which chemotherapeutic agents can be specifically targeted to cancer cells. In addition to the selection of antibody targets, ADCs offer a modular design that allows selection of ADC characteristics through the choice of linker chemistries, toxins, and conjugation sites. Many studies have indicated that release of toxins bound to antibodies via noncleavable linker chemistries relies on the internalization and intracellular trafficking of the ADC...
February 13, 2017: Bioconjugate Chemistry
https://www.readbyqxmd.com/read/28143835/oncolytic-adenoviral-delivery-of-an-egfr-targeting-t-cell-engager-improves-antitumor-efficacy
#13
Carlos A Fajardo, Sonia Guedan, Luis A Rojas, Rafael Moreno, Marcel Arias-Badia, Jana de Sostoa, Carl H June, Ramon Alemany
Antiviral immune responses present a major hurdle to the efficacious use of oncolytic adenoviruses as cancer treatments. Despite the existence of a highly immunosuppressive tumor environment, adenovirus-infected cells can nonetheless be efficiently cleared by infiltrating cytotoxic T lymphocytes (CTL) without compromising tumor burden. In this study, we tested the hypothesis that tumor infiltrating T cells could be more effectively activated and redirected by oncolytic adenoviruses which were armed with bispecific T cell-engager antibodies (BiTE antibodies)...
January 31, 2017: Cancer Research
https://www.readbyqxmd.com/read/28137467/engineering-bispecific-antibodies-with-defined-chain-pairing
#14
Simon Krah, Carolin Sellmann, Laura Rhiel, Christian Schröter, Stephan Dickgießer, Jan Beck, Stefan Zielonka, Lars Toleikis, Björn Hock, Harald Kolmar, Stefan Becker
Bispecific IgG-like antibodies can simultaneously interact with two epitopes on the same or on different antigens. Therefore, these molecules facilitate novel modes of action, which cannot be addressed by conventional monospecific IgGs. However, the generation of such antibodies still appears to be demanding due to their specific architecture comprising four different polypeptide chains that need to assemble correctly. This review focusses on different strategies to circumvent this issue or to enforce a correct chain association with a focus on common-chain bispecific antibodies...
January 27, 2017: New Biotechnology
https://www.readbyqxmd.com/read/28125314/bisfabs-tools-for-rapidly-screening-hybridoma-iggs-for-their-activities-as-bispecific-antibodies
#15
Sanket Patke, Ji Li, Peiyin Wang, Dion Slaga, Jennifer Johnston, Sunil Bhakta, Siler Panowski, Liping L Sun, Teemu Junttila, Justin M Scheer, Diego A Ellerman
Bispecific antibodies are a growing class of therapeutic molecules. Many of the current bispecific formats require DNA engineering to convert the parental monoclonal antibodies into the final bispecific molecules. We describe here a method to generate bispecific molecules from hybridoma IgGs in 3-4 days using chemical conjugation of antigen-binding fragments (Fabs) (bisFabs). Proteolytic digestion conditions for each IgG isotype were analyzed to optimize the yield and quality of the final conjugates. The resulting bisFabs showed no significant amounts of homodimers or aggregates...
January 26, 2017: MAbs
https://www.readbyqxmd.com/read/28119525/frequency-of-regulatory-t-cells-determines-the-outcome-of-the-t-cell-engaging-antibody-blinatumomab-in-patients-with-b-precursor-all
#16
J Duell, M Dittrich, T Bedke, T Mueller, F Eisele, A Rosenwald, L Rasche, E Hartmann, T Dandekar, H Einsele, M S Topp
Blinatumomab, can induce in 46,6% a complete haematological remission in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) resulting in a survival benefit when compared to chemotherapy. Only bone marrow blasts counts prior to therapy have shown a weak prediction of response. Here we investigated the role of regulatory T-cells (Treg) measured by CD4/CD25/FOXP3 expression in predicting the outcome of immunotherapy with the CD19 directed bispecific T-cell engager construct blinatumomab...
January 25, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28117014/bispecific-antibodies-bsabs-promising-immunotherapeutic-agents-for-cancer-therapy
#17
Deasmond Omane Acheampong, Christian Kweku Adokoh, Paulina Ampomah, Daniel S Agyirifor, Isaac Dadzie, Francis Armah-Arkah, Ernest Amponsah Asiamah
Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs...
January 19, 2017: Protein and Peptide Letters
https://www.readbyqxmd.com/read/28108597/bispecific-antibodies-and-antibody-drug-conjugates-adcs-bridging-her2-and-prolactin-receptor-improve-efficacy-of-her2-adcs
#18
Julian Andreev, Nithya Thambi, Andres E Perez Bay, Frank J Delfino, Joel H Martin, Marcus P Kelly, Jessica R Kirshner, Ashique Rafique, Arthur Kunz, Thomas Nittoli, Douglas MacDonald, Christopher Daly, William Olson, Gavin Thurston
The properties of cell surface proteins targeted by Antibody-drug conjugates (ADCs) have not been fully exploited; of particular importance are the rate of internalization and the route of intracellular trafficking. In this study we compared the trafficking of HER2, which is the target of the clinically approved ADC ado-trastuzumab emtansine (T-DM1), with that of prolactin receptor (PRLR), another potential target in breast cancer. In contrast to HER2, we found that PRLR is rapidly and constitutively internalized, and traffics efficiently to lysosomes, where it is degraded...
January 20, 2017: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/28100833/follicular-cd8-t-cells-accumulate-in-hiv-infection-and-can-kill-infected-cells-in-vitro-via-bispecific-antibodies
#19
Constantinos Petrovas, Sara Ferrando-Martinez, Michael Y Gerner, Joseph P Casazza, Amarendra Pegu, Claire Deleage, Arik Cooper, Jason Hataye, Sarah Andrews, David Ambrozak, Perla M Del Río Estrada, Eli Boritz, Robert Paris, Eirini Moysi, Kristin L Boswell, Ezequiel Ruiz-Mateos, Ilias Vagios, Manuel Leal, Yuria Ablanedo-Terrazas, Amaranta Rivero, Luz Alicia Gonzalez-Hernandez, Adrian B McDermott, Susan Moir, Gustavo Reyes-Terán, Fernando Docobo, Giuseppe Pantaleo, Daniel C Douek, Michael R Betts, Jacob D Estes, Ronald N Germain, John R Mascola, Richard A Koup
Cytolytic CD8 T cells play a crucial role in the control and elimination of virus-infected cells and are a major focus of HIV cure efforts. However, it has been shown that HIV-specific CD8 T cells are infrequently found within germinal centers (GCs), a predominant site of active and latent HIV infection. We demonstrate that HIV infection induces marked changes in the phenotype, frequency, and localization of CD8 T cells within the lymph node (LN). Significantly increased frequencies of CD8 T cells in the B cell follicles and GCs were found in LNs from treated and untreated HIV-infected individuals...
January 18, 2017: Science Translational Medicine
https://www.readbyqxmd.com/read/28100773/targeted-fc%C3%AE-r-mediated-clearance-by-a-biparatopic-bispecific-antibody
#20
Srinath Kasturirangan, G Jonah Rainey, Linda Xu, Xinwei Wang, Alyse Portnoff, Tracy Chen, Christine Fazenbaker, Helen Zhong, Jared Bee, Zhutian Zeng, Craig Jenne, Herren Wu, Changshou Gao
Soluble ligands have commonly been targeted by antibody therapeutics for cancers and other diseases. While monoclonal antibodies targeting such ligands can block their interactions with their cognate receptors, they can also significantly increase the half-life of their ligands by FcRn-mediated antibody recycling, thereby evading ligand renal clearance and requiring increasingly high antibody doses to neutralize the increasing pool of target. To overcome this issue, we generated a bispecific/biparatopic antibody (BiSAb) that targets two different epitopes on IL-6 to block IL-6 mediated signaling...
January 18, 2017: Journal of Biological Chemistry
keyword
keyword
60811
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"